Source - LSE Regulatory
RNS Number : 0317C
Niox Group PLC
06 October 2022
 

 

NIOX Group plc

("NIOX Group" or the "Company")

 

Result of General Meeting and Proposed Capital Reduction

 

6 October 2022

 

NIOX Group plc (AIM: NIOX) announces that at the General Meeting held earlier today, the resolutions proposed were duly passed by shareholders.

The Company will now seek approval for the Capital Reduction from the High Court. The court hearing is expected to be on 8 November 2022 and therefore the effective date of the Capital Reduction is expected to be 18 November 2022. These dates may be subject to change, and any changes will be notified via a Regulatory Information Service.

The passing of the second resolution considered at the General Meeting grants the Company authority to make market purchases of up to 10% the issued share capital as at 13 September 2022.  NIOX Group currently has no immediate plans to utilise this authority and further announcements would be made, as appropriate, should the Company intend to do so. 

The full text of the resolutions and meanings of capitalised items used in this announcement can be found in the shareholder circular published by the Company on 13 September 2022 which is available on the Company's website, www.investors.niox.com.

 

Contacts

 


NIOX

Ian Johnson, Executive Chairman                                                               

Michael Roller, Chief Financial Officer

Sarah Duncan, Company Secretary

 

Via Singer Capital Markets

Singer Capital Markets (Nominated Adviser & Broker)

Aubrey Powell / Jen Boorer

 

+44 (0) 20 7496 3000

 

 

 

About NIOX

Our ambition is to improve the quality of life of millions of people suffering from asthma. Asthma is one of the biggest healthcare issues globally with 340 million sufferers, many of whom are undiagnosed or misdiagnosed The Group is engaged in the design, development, and commercialisation of medical devices for the measurement of FeNO, a biomarker of inflammatory asthma. Our market leading device, NIOX VERO®, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis and management of asthma. NIOX VERO® is also the device of choice by leading clinical research organisations for respiratory studies. We passionately believe in empowering everyone to manage their health at home and will look to provide a device designed exclusively for home use. 

At present, NIOX provides products and services in around 50 countries. For more information, please visit www.investors.niox.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ROMFZMGGLVKGZZG
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJ Bell logo

Related Charts

Niox Group PLC (NIOX)

-1.00p (-1.40%)
delayed 09:36AM